179 related articles for article (PubMed ID: 22649145)
21. Reproductive endocrinology: triptorelin ovarian suppression during breast cancer chemotherapy.
Ginsburg ES; Partridge AH
Nat Rev Endocrinol; 2011 Sep; 7(11):637-8. PubMed ID: 21931373
[No Abstract] [Full Text] [Related]
22. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
Leonard RCF; Adamson DJA; Bertelli G; Mansi J; Yellowlees A; Dunlop J; Thomas GA; Coleman RE; Anderson RA;
Ann Oncol; 2017 Aug; 28(8):1811-1816. PubMed ID: 28472240
[TBL] [Abstract][Full Text] [Related]
23. [Breast cancer and fertility: critical review, considerations and perspectives].
This P
Bull Cancer; 2008 Jan; 95(1):17-25. PubMed ID: 18230566
[TBL] [Abstract][Full Text] [Related]
24. Estrogen and lipid profile in patients with endometriosis treated by GnRH agonist.
Al-Omari WR; Nassir UN; Sulaiman WR
Int J Gynaecol Obstet; 1999 Aug; 66(2):191-2. PubMed ID: 10468351
[No Abstract] [Full Text] [Related]
25. [Premature ovarian failure after chemotherapy for breast cancer].
Mathelin C; Brettes JP; Diemunsch P
Bull Cancer; 2008 Apr; 95(4):403-12. PubMed ID: 18495569
[TBL] [Abstract][Full Text] [Related]
26. Reply to Z. Blumenfeld et al.
Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2013 Oct; 31(29):3722-3. PubMed ID: 24002513
[No Abstract] [Full Text] [Related]
27. Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies.
Castelo-Branco C; Rabanal A; Nomdedeu B; Durán M; Arigita M; Balasch J
Fertil Steril; 2009 Oct; 92(4):1260-1263. PubMed ID: 19732883
[TBL] [Abstract][Full Text] [Related]
28. [Role of GnRH agonists in preserving female fertility].
Thomin A; Torre A; Daraï É; Chabbert-Buffet N
J Gynecol Obstet Biol Reprod (Paris); 2014 Apr; 43(4):267-74. PubMed ID: 24321862
[TBL] [Abstract][Full Text] [Related]
29. [Adjuvant chemotherapy of premenopausal breast cancer with LH-RH analogue for ovarian protection--a case report].
Asaga S; Ando J; Arai T; Fujii H
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1069-72. PubMed ID: 16044976
[TBL] [Abstract][Full Text] [Related]
30. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
31. The role of ovarian ablation in the adjuvant therapy of breast cancer.
Tan SH; Wolff AC
Curr Oncol Rep; 2008 Jan; 10(1):27-37. PubMed ID: 18366958
[TBL] [Abstract][Full Text] [Related]
32. Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
Lambertini M; Del Mastro L; Viglietti G; Pondé NF; Solinas C; de Azambuja E
Curr Treat Options Oncol; 2017 Jan; 18(1):4. PubMed ID: 28185173
[TBL] [Abstract][Full Text] [Related]
33. New hope for young breast cancer patients.
Peres J
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214565
[No Abstract] [Full Text] [Related]
34. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
Urruticoechea A; Arnedos M; Walsh G; Dowsett M; Smith IE
Breast Cancer Res Treat; 2008 Aug; 110(3):411-6. PubMed ID: 17851753
[TBL] [Abstract][Full Text] [Related]
35. Influence of physiologic hormonal modification and of hormonal treatment in a patient with a history of migraine with aura.
Maggioni F; Palmieri A; Tropea M; Zanchin G
J Headache Pain; 2008 Apr; 9(2):129-31. PubMed ID: 18265933
[TBL] [Abstract][Full Text] [Related]
36. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.
Lambertini M; Ceppi M; Poggio F; Peccatori FA; Azim HA; Ugolini D; Pronzato P; Loibl S; Moore HC; Partridge AH; Bruzzi P; Del Mastro L
Ann Oncol; 2015 Dec; 26(12):2408-19. PubMed ID: 26347105
[TBL] [Abstract][Full Text] [Related]
37. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
[TBL] [Abstract][Full Text] [Related]
38. [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].
Gris-Martínez JM; Trillo-Urrutia L; Gómez-Cabeza JJ; Encabo-Duró G
Med Clin (Barc); 2016 Feb; 146(3):97-103. PubMed ID: 26194532
[TBL] [Abstract][Full Text] [Related]
39. Triptorelin in the management of prostate cancer.
Ploussard G; Mongiat-Artus P
Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
[TBL] [Abstract][Full Text] [Related]
40. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis.
Vitek WS; Shayne M; Hoeger K; Han Y; Messing S; Fung C
Fertil Steril; 2014 Sep; 102(3):808-815.e1. PubMed ID: 25044080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]